Global Healthcare Growth Will Spur CDMO Expansion While Tempering Risks

AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts
Published
26 Jan 25
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
₹694.85
18.3% overvalued intrinsic discount
07 Aug
₹821.85
Loading
1Y
92.8%
7D
-3.2%

Author's Valuation

₹694.8

18.3% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on30 Jul 25
Fair value Increased 23%

The consensus analyst price target for Laurus Labs has been raised from ₹564.31 to ₹698.46, primarily reflecting stronger profitability as evidenced by a significant increase in net profit margin and a lower future P/E ratio, indicating improved earnings outlook and valuation. What's in the News Board meeting scheduled to consider and approve un-audited financial results for the quarter ended June 30, 2025.

Shared on01 May 25
Fair value Increased 0.78%

AnalystConsensusTarget has decreased revenue growth from 16.8% to 13.6%, decreased profit margin from 14.1% to 11.0% and increased future PE multiple from 34.3x to 48.4x.

Shared on23 Apr 25
Fair value Increased 2.35%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to -0.0%.

Shared on17 Apr 25
Fair value Decreased 1.22%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 5.42%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 9.06%

AnalystConsensusTarget has increased future PE multiple from 30.2x to 34.2x.